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Glioblastomas (GBMs) are the most aggressive and lethal primary astrocytic tumors
in adults, with very poor prognosis. Recurrence in GBM is attributed to glioblastoma
stem-like cells (GSLCs). The behavior of the tumor, including proliferation, progression,
invasion, and significant resistance to therapies, is a consequence of the self-renewing
properties of the GSLCs, and their high resistance to chemotherapies have been
attributed to their capacity to enter quiescence. Thus, targeting GSLCs may constitute
one of the possible therapeutic challenges to significantly improve anti-cancer treatment
regimens for GBM. Ca2+ signaling is an important regulator of tumorigenesis in
GBM, and the transition from proliferation to quiescence involves the modification
of the kinetics of Ca2+ influx through store-operated channels due to an increased
capacity of the mitochondria of quiescent GSLC to capture Ca2+. Therefore, the
identification of new therapeutic targets requires the analysis of the calcium-regulated
elements at transcriptional levels. In this review, we focus onto the direct regulation of
gene expression by KCNIP proteins (KCNIP1–4). These proteins constitute the class
E of Ca2+ sensor family with four EF-hand Ca2+-binding motifs and control gene
transcription directly by binding, via a Ca2+-dependent mechanism, to specific DNA
sites on target genes, called downstream regulatory element (DRE). The presence of
putative DRE sites on genes associated with unfavorable outcome for GBM patients
suggests that KCNIP proteins may contribute to the alteration of the expression of
these prognosis genes. Indeed, in GBM, KCNIP2 expression appears to be significantly
linked to the overall survival of patients. In this review, we summarize the current
knowledge regarding the quiescent GSLCs with respect to Ca2+ signaling and discuss
how Ca2+ via KCNIP proteins may affect prognosis genes expression in GBM. This
original mechanism may constitute the basis of the development of new therapeutic
strategies.
Keywords: Ca2+ signaling, neuronal Ca2+ sensors, KCNIP, glioblastoma multiform, cancer stem cells (CSC),
quiescence
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INTRODUCTION
Among tumors of the central nervous system, glioblastomas
(GBMs) are the most aggressive and lethal primary astrocytic
tumors in adults, with very poor prognosis (Louis et al.,
2016; Lapointe et al., 2018). More than 90% of the patients
show recurrence after therapies combining surgical resection,
radiotherapy, and temozolomide (TMZ)-based chemotherapy,
and the mean survival period rarely exceeds 2 years (Stupp et al.,
2005). According to the cancer stem cell model, recurrence in
GBM is attributed to a small sub-population of tumor cells called
glioblastoma stem-like cells (GSLCs). These GSLCs have stem-
like properties and are responsible for the initiation and the
growth of the tumors (Visvader and Lindeman, 2008). Indeed,
the GSLCs provide all the subtypes of cells that comprise the
tumor including some pseudo-endothelial cells (Ricci-Vitiani
et al., 2010). GSLCs are characterized by a molecular signature
which combines markers of neural and/or embryonic stem
cells and of mesenchymal cells. Numerous studies support the
proposal that the behavior of the tumor, including proliferation,
progression, invasion, and significant resistance to therapies,
is determined by the self-renewing properties of the GSLCs
(Stupp et al., 2005; Bao et al., 2006; Hegi et al., 2006; Stupp
and Hegi, 2007; Murat et al., 2008). More importantly, this high
resistance capacity to TMZ treatment have been attributed to
slow cycling or relatively quiescent GSLCs (Pistollato et al., 2010;
Deleyrolle et al., 2011). Quiescent GSLCs have been identified
in vivo in a mouse model of GBM (Chen et al., 2012) and
in human GBM tumors (Ishii et al., 2016). Thus, targeting
GSLCs and their stem cell-like properties may constitute one
of the possible therapeutic challenges to significantly improve
anti-cancer treatment regimens for GBM.
Ca2+ is a crucial second messenger (Carafoli and Krebs,
2016) that controls a wide variety of cell functions from cell
proliferation and apoptosis to organogenesis (Berridge et al.,
2000; Machaca, 2011; Moreau et al., 2016). Thus, the intracellular
Ca2+ concentration ([Ca2+]i) is tightly regulated and involves
Ca2+ channels, pumps, and exchangers both at the plasma
membrane and at the membrane of endoplasmic reticulum,
mitochondria, or Golgi apparatus (Bootman, 2012; Humeau
et al., 2018). In addition, changes in [Ca2+]i do not proceed
in a stereotypical manner. The Ca2+ signal can be described
by its amplitude (variations of [Ca2+]i levels) and by its spatial
(sources of Ca2+; organelles where changes occur) and time-
dependent (duration, frequency) components (Berridge, 1992;
Haiech et al., 2011; Smedler and Uhlén, 2014; Monteith et al.,
2017). The remodeling of Ca2+ signaling contributes also to
cancer hallmarks such as excessive proliferation, survival, or
resistance to cell death (Roderick and Cook, 2008; Prevarskaya
et al., 2014) and accumulating evidence suggests that Ca2+ is
also an important positive regulator of tumorigenesis in GBM
(Robil et al., 2015; Leclerc et al., 2016). Interestingly, screening
of the Prestwick Chemical library identified bisacodyl, an organic
compound used as a stimulant laxative drug, with cytotoxic
effect on quiescent GSLCs (Zeniou et al., 2015). Bisacodyl
inhibits Ca2+ release from inositol 1,4,5-triphosphate-dependent
Ca2+ stores without affecting the store-operated Ca2+ entry
(SOCE) (Dong et al., 2017). These data exemplify the fact that
Ca2+ channels, pumps, and exchangers may represent potential
therapeutic targets. In this review, we will summarize the current
knowledge regarding the quiescent GSLCs with respect to Ca2+
signaling and describe an original mechanism by which Ca2+ can
activate some genes involved in the prognosis of GBM in order
to propose new strategies to explore the molecular basis of GBM
development for therapeutic issues.
TRANSITION FROM PROLIFERATION TO
QUIESCENCE AND Ca2+ SIGNALING
Quiescent cells are non-proliferative cells, arrested in a specific
phase of the cell cycle called G0 (Coller et al., 2006). Quiescence
is not a prolonged G1 phase and in contrary to the cell-
cycle arrest observed in differentiation or senescence, it is
reversible. Transcriptional profiling data reveal that quiescent
stem cells are characterized by a common set of genes which
are either downregulated, these are genes associated with
cell-cycle progression (i.e., CCNA2, CCNB1, and CCNE2), or
upregulated and classified as tumor suppressors, including the
cyclin-dependent kinase inhibitor p21 (CDKN1A) and the G0/G1
switch gene 2 (G0S2) (Yamada et al., 2012; Cheung and Rando,
2013). Quiescence represents a strategy for GSLCs to evade
killing. It is thus vital to better characterize the quiescent
GSLCs and to understand the mechanisms involved in the
transition from a proliferative to a quiescence state. Quiescence
is actively regulated by signals provided by the stem cell
microenvironment. In GBM, quiescent cells are found close to
necrotic tissues, in specific niches characterized by a hypoxic
(Pistollato et al., 2010; Persano et al., 2011; Ishii et al., 2016) and
acidic microenvironment (Garcia-Martin et al., 2006; Honasoge
et al., 2014).
A recent study suggests that Ca2+ is an important regulator
of the balance between quiescence and proliferation in
hematopoietic stem cell (HSC) (Umemoto et al., 2018). In
HSCs, re-entry into cell-cycle requires Ca2+ influx through
Cav1 voltage-dependent Ca2+ channel and the resultant
activation of mitochondria. Recent findings in our group
showed that Ca2+ signaling is also required for GBM stem cells
quiescence. On GSLCs lines, established from surgical resections
of primary GBMs, we showed that change in Ca2+ homeostasis
is an important actor of the transition from proliferation to
quiescence. In order to analyze the signals underlying this
switch, we modified the culture condition by lowering the
extracellular pH from pH 7.5 to 6.5. GSLCs kept in such
conditions for 5 days enter G0. This simple protocol allowed
to reversibly maintain GSLCs in a proliferating or in quiescent
state (Zeniou et al., 2015; Aulestia et al., 2018). A RNAseq
analysis, focusing on the Ca2+ toolkit genes (Robil et al., 2015),
established the transcriptional profiles of these proliferative
and quiescent GSLCs and revealed that genes regulating
plasma membrane Ca2+ channels (CACNA2D1 and ORAI2)
and mitochondrial Ca2+-uptake (MCU, MICU1, MICU2, and
VDAC1) are downregulated in quiescence while others are
upregulated (CACNB1, CAPS, and SLC8B1). A functional
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analysis through a bioluminescent Ca2+ imaging approach
showed that quiescence in GSLCs does not involve Cav1
channels like in HSCs, but is rather due to the modification
of the kinetics of the store-operated Ca2+ entry (SOCE),
mediated by plasma membrane ORAI channels associated
with the ER membrane protein STIM1. The inhibition of
store-operated channels (SOC) by SKF96365 triggers quiescence,
further supporting the crucial role of SOC in quiescence in
GSLCs. Interestingly, the use of bioluminescent Ca2+ reporter
targeted to mitochondria revealed that this change in SOCE
kinetics is due to an increased capacity of quiescent GSLCs’
mitochondria to capture Ca2+ and not to the modification of
the SOCE mechanism itself (Aulestia et al., 2018). These data
highlight the importance of mitochondria as regulator of Ca2+
homeostasis.
Over the past decade, many studies have identified changes in
the expression levels of proteins involved in Ca2+ homeostasis
such as Ca2+ channels, pumps, and exchangers and established
that some of these proteins contribute to tumorigenesis through
regulation of proliferation, migration, or apoptosis (Monteith
et al., 2012; Leclerc et al., 2016). As a second messenger, Ca2+
is also an important regulator of gene expression. This occurs
either indirectly, via changes in the transactivating properties of
transcription factors following the activation of Ca2+-dependent
kinases and/or phosphatases (Dolmetsch, 2001; West et al., 2001;
Kornhauser et al., 2002; Spotts et al., 2002), or directly via EF
hand Ca2+-binding proteins which belongs to a group of four
proteins (KCNIP1–4) (Mellström et al., 2008). The identification
of new therapeutic targets now requires not only to target the
identified proteins but also to analyze the molecular mechanisms
responsible for the changes in gene expression observed in cancer
cells. In this review, we choose to focus on the direct mode of
action of Ca2+ on transcription with the implication of KCNIPs
in GBM.
THE FAMILY OF NEURONAL Ca2+
SENSORS: KCNIPs
Potassium channel-interacting proteins (KCNIPs), which
constitute the class E of Ca2+ sensor family, are globular proteins
of 217–270 amino acids in size, with variable N- and C-termini
and a conserved core domain containing four EF-hand Ca2+-
binding motifs (EF-1, EF-2, EF-3, and EF-4). Among the four
EF hands, EF-1 is not able to bind Ca2+ (Buxbaum et al., 1998;
Carrión et al., 1999; An et al., 2000). Drosophila melanogaster has
a single Kcnip, whereas mammals have four KCNIPs (KCNIP1–4)
and several alternatively spliced variants (Burgoyne, 2007). In
mammals, the four KCNIPs are predominantly expressed in
adult brain, with specific or overlapping patterns according
to the tissues (Rhodes, 2004; Xiong et al., 2004; Pruunsild
and Timmusk, 2005). KCNIP3, also called calsenilin, KChIP3,
and DREAM [i.e., Downstream Regulatory Element (DRE)
Antagonist Modulator] is also found in the thyroid gland
(Dandrea et al., 2005; Rivas et al., 2009) and in the hematopoietic
progenitor cells (Sanz, 2001). KCNIP2 and KCNIP3 are found in
T and B lymphocytes (Savignac et al., 2005, 2010). During mouse
development, Kcnip3 transcript first occurs at E10.5 (Spreafico
et al., 2001) and Kcnip1, 2, and 4 are not detected before E13
(Pruunsild and Timmusk, 2005). In the fish Danio rerio, the
embryonic expressions of kcnip1b and kcnip3 are not detectable
before somitogenesis (Stetsyuk et al., 2007) and in the amphibian
Xenopus laevis among the four kcnips, only kcnip1 is expressed
at all developmental stages, from fertilized egg to the tadpole
stages. By contrast, the transcripts for kcnip2, kcnip3, and kcnip4
are expressed at later stages, after the specification of neural
territories (Néant et al., 2015).
KCNIP proteins are known to control gene transcription
directly by binding, via a Ca2+-dependent mechanism, to specific
DNA sites, called DRE, of target genes. DRE sites are localized
in the proximal 5′ sequence of the gene, downstream of the
TATA box and upstream of the start codon, with the sequence
GTCA forming the central core of the DRE site (Carrión et al.,
1999; Ledo et al., 2000). This mechanism has been particularly
well described for KCNIP3 (DREAM). When the intracellular
Ca2+ level is low, KCNIP3 is bound as tetramer to the DRE
sites, acting mainly as a transcriptional repressor. An increase in
intracellular Ca2+ leads to dissociation of the KCNIP3 tetramer
from its DRE site, thus allowing transcription (Carrión et al.,
1999). KCNIP3 can affect transcription by acting either as a
transcriptional repressor (Carrión et al., 1999; Link, 2004) or
activator (Scsucova, 2005; Cebolla et al., 2008). In a more recent
study, KCNIP3 has been shown to be required for human
embryonic stem cells (hESCs) survival and to maintain hESCs
pluripotency (Fontán-Lozano et al., 2016). KCNIP3 was initially
the only Ca2+ sensor known to bind to DRE sites and to
directly regulate transcription in a Ca2+-dependent manner
(Mellström and Naranjo, 2001). However, all the four KCNIPs
exhibit DRE-binding site affinity as homo or heterotetramers
and act as Ca2+-dependent transcriptional regulators (Osawa
et al., 2001; Craig et al., 2002; Link, 2004), allowing functional
redundancy. KCNIP2 and KCNIP3 interactions are indirectly
evidenced by two-hybrid and immunoprecipitation experiments
(Savignac et al., 2005) and by the fact that KCNIP3 and
KCNIP2 are both able to physically interact with EF-hand
mutated KCNIP3 and that such associations still inhibit
DRE-dependent gene expression (Gomez-Villafuertes, 2005;
Savignac et al., 2005). In vivo studies also argue for the
existence of compensatory mechanisms and the formation
of functional KCNIP heterotetramers. Particularly, while in
cortico-hippocampal neurons from Kcnip3 knockdown mice, the
expression levels of KCNIP3 target genes such as Npas4 and c-
fos are not significantly modified, the additional invalidation of
Kcnip2 with an antisense lentiviral vector (in this Kcnip3 KO
context) results in a significant increase in the expression of
these KCNIP3-dependent target genes (Mellström et al., 2014).
In amphibian embryos, we demonstrated that Kcnip1 binds DRE
sites in a Ca2+-dependent manner. Kcnip1 is the earliest kcnip
gene expressed in X. laevis embryo. Its transcripts are timely and
spatially present in the presumptive neural territories. In this
in vivo model, loss of function experiments indicate that Kcnip1
is a Ca2+-dependent transcriptional repressor that controls the
size of the neural plate by regulating the proliferation of neural
progenitors (Néant et al., 2015).
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KCNIP PROTEINS IN GLIOBLASTOMA
To the best of our knowledge, no published work has analyzed
the expression of KCNIPs in GSLCs or more generally in cancer
stem cells. Using the UALCAN server (Chandrashekar et al.,
2017), it was possible to compare gene expression in normal
brain tissues versus GBM multiform. KCNIP1–4 are expressed
in normal tissues at comparable levels. Interestingly, in GBM
tissues while KCNIP1 is significantly upregulated compared to
its levels in normal brain tissues, KCNIP2 and KCNIP3 are
strongly downregulated (Table 1). Although KCNIP4 expression
appears downregulated in GBM, the results are not statistically
significant. This is probably due to large variability of KCNIP4
expression in normal brain tissues and the small number of
samples analyzed. In terms of survival, only KCNIP2 expression
is relevant. Among GBM patients, those with high KCNIP2
expression appear to have a significant reduction in their overall
survival time (UALCAN analysis). A recent study incidentally
provides additional information on KCNIP expression in BT189
GSLC (Wang et al., 2018). Wang and coworkers analyzed the
function of ING5, an epigenetic regulator overexpressed in GBM,
and showed that ING5 promotes GSLCs self-renewal capabilities.
Using the fluorescent Ca2+ probe fluo3, these authors showed
that [Ca2+]i increases in cells overexpressing ING5. This increase
TABLE 1 | KCNIP genes expression in glioblastoma multiform.
Gene Gene expression in normal
brain tissues (n = 5)
maximum – median – minimum
Gene expression in glioblastoma
multiform (GBM) tissues (n = 156)
maximum – median – minimum
Statistical significance at 0.05
KCNIP1 42.014 – 38.869 – 34.986 229.234 – 50.603 – 0.603 1.829 E−04
KCNIP2 85.765 – 68.456 – 16.25 23.856 – 6.02 – 0.222 4.978 E−02
KCNIP3 51.355 – 51.275 – 49.132 33.57 – 8.244 – 0.43 4.279 E−09
KCNIP4 77.262 – 53.813 – 10.084 25.877 – 4.346 – 0.501 7.312 E−02
Gene expression is presented as a number of transcripts for each KCNIP genes per million of total transcripts. Data extracted using the UALCAN
server (http://ualcan.path.uab.edu/index.html). Genes and proteins symbols are formatted according to the specific conventions particular to each organism
(www.biosciencewriters.com).
TABLE 2 | Candidate genes with putative DRE site and expressed in GSLCs.
Gene Function Expression in
GSLCs
Reference Number of putative
DRE sites
Sense/position
in bpa
Sequence in Homo sapiens (the
core sequence is underlined)
MCUb Mitochondrial
calcium uniporter
Downregulated in
the quiescent state
Aulestia et al., 2018 3 S/−240
AS/−207
S/−101
5′ tttgggtgtcaattatgggt 3′ 5′
cccgtaattgactatgtccc 3′ 5′
caactcagtcaagggcttta 3′
MCUb Mitochondrial
calcium uniporter
beta subunit
2 AS/−70 AS/−36 5′ ccaggcgctgacgaggagcc 3′ 5′
tgcgccgctgacgcctgcgg 3′
MICU1 Mitochondrial
calcium uptake 1
NF
MICU2 Mitochondrial
calcium uptake 2
1 AS/−199 5′ ggatgggatgacaggaagag 3′
VDAC1 Voltage-dependent
anion channel 1
NF
TRPC3 Transient receptor
potential cation
channel subfamily
C member 3
Upregulated by
ING5
Wang et al., 2018 NF
TRPC4 Transient receptor
potential cation
channel subfamily
C member 4
4 AS/−620
AS/−582
S/−355 S/−76
5′ ggctggatgacggctggctg 3′ 5′
cactggctgacctcaagcag 3′ 5′
atccgctgtcagccgtggga 3′ 5′
ccgcgccgtcagtcctcgga 3′
TRPC5b Transient receptor
potential cation
channel subfamily
C member 5
4 S/−478 S/−465
S/−451
AS/−421
5′ cctacagtgtcagctacccc 3′ 5′
ctacccctgtcagtttcccc 3′ 5′
ttccccgtgtcagtttcttc 3′ 5′
attgtgtgtgactggctgcg 3′
TRPM1 Transient receptor
potential cation
channel subfamily
M member 1
1 S/−34 5′ ccgagggagtcagcagggtg 3′
aPosition upstream from the ATG; S, sense; AS, anti-sense; bputative DRE sites in close proximity. NF, not found, in accordance with the criteria in proximal 5′ upstream
sequence between the tata box and the start codon (see details in text).
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in the resting Ca2+ level is required to maintain GSLCs’
self-renewal. Conversely, ING5 knockdown results in a strong
reduction of the resting [Ca2+]i. To decipher further how ING5 is
acting, they performed the transcriptomic analysis of GSLC cells
where ING5 is knockdown. Among the differentially expressed
genes, several Ca2+ channels were identified as upregulated
by ING5, including some subunits of L and P/Q types of
voltage-gated Ca2+ channels (CACNA1F, 1S, 1D, and 1C and
CACN1A, respectively) and of transient receptor potential cation
channels (TRPC3, C5, C4, and M1). Of note, close examination
of this list revealed that KCNIP1–4 are indeed expressed in the
BT189 GSLCs, although with different expression levels, and that
KCNIP2 is upregulated by ING5 in this GLSC (see Supplementary
Table S1 in Wang et al., 2018).
These data suggest a role of KCNIP proteins in stemness
maintenance and dormant status of the GSLCs. The importance
of KCNIPs in GBM is further emphasized by the presence of
potential DRE sites within the proximal promoter of MCU and
MICU2, two genes downregulated in quiescent GSLCs (Aulestia
et al., 2018) and within the proximal promoters of TRPC5,
TRPC4, and TRPM1, genes from the TRP family upregulated by
the epigenetic factor ING5 in BT189 GSLC (Wang et al., 2018;
Table 2).
REGULATION OF GBM PROGNOSIS
GENES BY KCNIP PROTEINS
Ion channels are now considered as important actors in
cancers. Recent studies using microarray datasets of glioma
samples obtained from the CGGA (Chinese Glioma Genome
Atlas) and the TCGA (The Cancer Genome Atlas) identified
genes belonging to the Ca2+ signaling machinery as new
candidate genes that can predict GBM patients with high risk
of unfavorable outcome (Wang et al., 2016; Zhang et al.,
2017, 2018). These genes, listed in Table 3, are ion channels
TABLE 3 | Candidate genes associated with unfavorable prognosis in GBM.
Gene Function Role in GBM Reference Number of putative
DRE sites
Sense/position in
bpa
Sequence in Homo sapiens
(core sequence underlined)
CACNA1H Cav3.2; T-type
Ca2+ channel;
Ca2+ homeostasis
Over-expression
associated with
worse prognosis
Zhang et al., 2017 1 AS/−72 5′tccgcggtgaccgcgccg3′
KCNN4b KCa3.1; voltage-
independent
potassium
Ca2+-activated
channel
Over-expression
associated with
worse prognosis,
confers invasive
phenotype.
Turner et al., 2014;
Wang et al., 2016
4 S/−359 AS/−334
S/−166 AS/−94
5′ggtgtgtgtcacaaagtac3′
5′ttgtgtgtgacaaagccca3′
5′cctggccgtcaccactccc3′
5′agcaggctgacgacctgca3′
KCNB1 Kv2.1; potassium
voltage-gated
channel; delayed
rectifier potassium
channel
Downregulated in
gliomas. Correlated
with malignant
progression when
associated with
KCNN4 and
KCNJ10
Wang et al., 2016 2 AS/−137 AS/−48 5′acggccgtgacgcgcgccc3′
5′cgtcgagtgacagcggcct3′
KCNJ10 Kir4.1; potassium
voltage-gated
channel;
ATP-dependent
inwardly rectifier;
potassium buffering
in glial cells
Downregulated in
gliomas, correlated
with malignant
progression when
associated with
KCNN4 and
KCNB1
NF
PRKCG Protein kinase Cγ;
serine/threonine
protein kinase
activated by Ca2+
and diacylglycerol
Belong to a
co-expression
network genes that
can serve as
prognostic factors
for GBM
Zhang et al., 2018 NF
PRKCB Protein kinase Cβ;
serine/threonine
protein kinase
activated by Ca2+
and diacylglycerol
1 AS/−168 5′gggcgagtgacagccccgg3′
CAMK2Ac Ca2+-calmodulin-
dependent protein
kinase IIα
3 AS/−192 S/−133
S/−129
5′tggatgctgacgaaggctc3′
5′ggctcgtcagtcaaaccgg3′
aPosition upstream from the ATG; S, sense; AS, anti-sense; bputative DRE sites in close proximity; ctwo putative DRE sites in tandem. NF, not found, in accordance with
the criteria in proximal 5′ upstream sequence between the tata box and the start codon (see details in text).
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FIGURE 1 | Putative DRE sites for two prognosis genes KCNN4 and CAMK2A. The proximal promoters of primates (human, chimpanzee, and rhesus monkey) and
mouse are highly conserved for KCNN4 and CAMK2A genes, the putative DRE-binding sites within these proximal promoters are positioned regarding to ATG
(numbers in italic), the lengths of the 5′ fragment sequences are expressed in bp, and the yellow arrow gives the sequence orientation (see Table 3 for DRE
sequence details). A point mutation (T to C) in a “sense” DRE site within rhesus monkey sequence is mentioned by the gray arrow.
genes namely CACNA1H, a T-type Ca2+ channel (Cav3.2);
KCNN4, a potassium Ca2+-activated channel (KCa3.1); KCNB1,
a voltage-gated potassium channel (Kv2.1); KCNJ10, a potassium
Ca2+-activated channel (Kir4.1); and classified as Ca2+-binding
protein; PRKCG, Ca2+-dependent serine/threonine protein
kinase Cγ (PKCγ); PRKCB, Ca2+-dependent serine/threonine
protein kinase Cβ (PKCβ); and CAMK2A, the Ca2+-calmodulin-
dependent protein kinase IIα. KCNIP proteins are known to
control gene transcription directly by binding to DRE sites. To
test whether KCNIP proteins may be involved in the regulation
of the expression of these selected prognosis genes, we searched
for the presence of DRE sites within their proximal promoters.
The CACNA1H and PRKCB genes present both one DRE
potential site in their proximal promoter and KCNB1 presents
two DRE-binding sites (Table 3). More exciting are the three
and four putative DRE sequences exhibited by CAMK2A and
KCNN4, respectively, ideally positioned between the TATA box
and the start codon, within the highly conserved sequence
of proximal promoter in primates (Figure 1). The CAMK2A
proximal promoter is also particularly conserved in mouse
compared to human (87%), their DRE sites respect orientation
and repartition, even for tandem organization. This promising
observation has to be tested for KCNIP binding efficiency.
Recent evidence argues for the existence of functional DRE
sites within the CAMK2A proximal promoter. KCNIP3 mutants
with two amino acids substitution in the EF-hands two, three,
and four are unable to respond to Ca2+ and function as
a constitutively dominant active (daDREAM) transcriptional
repressor (Savignac et al., 2005). In transgenic mice with neuronal
expression of this daDREAM, the CAMK2A mRNA level is
reduced by 1.7-fold compared to wild type (Benedet et al., 2017).
Mouse promoter for KCNN4 is conserved (79%), but in a lesser
extend concerning DRE sequences. These sequence alignments
for proximal promoters let guess a putative regulatory role of
KNCIPs in the expression of some prognosis genes in GBM. Of
note, not all of these prognosis genes exhibit DRE-like sites, as
no DRE putative sequence was detected for KCNJ10 or PRKCG
(Table 3), suggesting that KCNIPs are not the only transcriptional
regulators directly implicated in the regulation of these prognosis
genes, but the hypothesis of their contribution remains attractive.
It is noteworthy that the previous results were obtained using
transcriptomic data issued from DNA chips. When using the
portal UALCAN (Chandrashekar et al., 2017) interfaced with the
TCGA data base of transcriptomic cancer profiles obtained by
RNA-seq techniques, only CACNA1H and KCNN4 expression
levels are correlated with significant differences in survival
curves. It is noticeable that these two genes present one and
three DRE sites, respectively. Anyhow, the presence of these
putative DRE sites on prognosis genes, suggests that remodeling
of Ca2+ homeostasis in GBM stem cells may contribute to the
alteration of the expression of these prognosis genes. These
preliminary observations urge for a more complete analysis
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taking into account the high level of false negatives when using
the transcriptomic signatures built from DNA chip data.
PERSPECTIVES/PROSPECT ON KCNIPS
IN GBM
Although no specific data are available for KCNIPs’ function
in GBM or even cancers, one can speculate taking into
account published functions of KCNIP in other cell types.
KCNIPs are in fact multifunctional EF hand Ca2+-binding
proteins and according to their interaction partners and
subcellular localization one can discriminate at least three main
functions: (1) regulation of cellular excitability, (2) regulation of
intracellular signaling, and (3) control of transcription.
Control of Cellular Excitability
The control of cellular excitability which involves the formation
of a macromolecular signaling complex between KCNIP1 or 2,
the A-type Kv4 potassium channel, and the T-type Ca2+ channel
Cav3 (Anderson et al., 2010a,b) is unlikely to occur in GSLCs.
Indeed, investigation of the electrophysiological properties of
glioma cells revealed the absence of A-type potassium channels
in these cells (Bordey and Sontheimer, 1998). Therefore, only
the two other functions of KCNIP may be relevant to GBM
physiology.
Regulation of Intracellular Ca2+
Signaling
In cardiomyocytes, KCNIP2 participates in the modulation of
Ca2+ release through ryanodine receptors (RyR) by interacting
with the ryanodine modulator, presenilin (Nassal et al., 2017).
The presenilin/KCNIP3 complex has also been shown to
modulate IP3-mediated Ca2+ release (Leissring et al., 2000).
We have already shown that the unique drug able to kill
quiescent GSLCs acts through a modulation of IP3 signaling
(Dong et al., 2017).
Control of Transcription
As mentioned above, all KCNIPs can bind to DRE sites on
DNA and directly control transcription. KCNIP3 (DREAM)
can also interact with other transcription factors such as
CREB and therefore affects transcription of genes that do not
contain DRE sites (review in Rivas et al., 2011). Interestingly,
in cardiomyocytes, it has been shown that the complex
Ca2+/CAMK2 regulates nuclear translocation of KCNIP3
(Ronkainen et al., 2011). As CAMK2A has been identified as a
prognosis gene in GBM (Table 3), such a mechanism is likely to
occur in GBM.
In conclusion, since no experimental data exists for the
moment in the literature concerning the function of KCNIP
family in GBM, this opens a new field of research. In other
models, KCNIPs have pleiotropic effects. Their well-known role
as transcriptional repressors, and the presence of DRE sites in
the promoter region of some GBM prognosis genes argue for
a transcriptional function of KCNIPs in GBM. However, non-
transcriptional roles have also to be considered more closely in
the future.
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